In the News COMPANY In the News TOBA III Roundtable Discussion: Thomas Zeller, MD, Marianne Brodmann, MD (PI), and Michael Lichtenberg, MD Tack Endovascular System: FDA Approved TOBA II 12-month pivotal trial data, presented by Dr. William A. Gray Post-PTA Dissection: Clinical Impact, Identification, and Repair Intact Vascular Receives Conditional FDA Approval for TOBA II Study of Tack System Intact Vascular’s Tack Endovascular System Supported by 12-Month TOBA Data TOBA II shows repairing dissections after angioplasty “clearly augments” outcomes for PAD patients. Using the Tack Endovascular System to treat vessel dissection Intact Vascular Announces Conditional FDA Approval for TOBA II Study and Enrolment of First Patients Positive 12-Month Results of TOBA Clinical Trial TOBA II shows repairing dissections after angioplasty “clearly augments” outcomes for PAD patients. Start-Ups Across Health Care: Intact Vascular Inc. Optimizing balloon angioplasty for peripheral arterial disease PURPOSE–BUILT. PRECISION REPAIR. PRESERVES OPTIONS.